La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Candel Therapeutics Gestione

Gestione criteri di controllo 4/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Paul-Peter Tak

Amministratore delegato

US$1.5m

Compenso totale

Percentuale dello stipendio del CEO	45.1%
Mandato del CEO	4yrs
Proprietà del CEO	0.4%
Durata media del management	2.5yrs
Durata media del Consiglio di amministrazione	5.8yrs

Aggiornamenti recenti sulla gestione

Recent updates

Candel Therapeutics: Innovative Cancer Therapies, But Short Cash Runway

Jul 01

Candel Therapeutics: CAN-2409 May Go Beyond Scope Of Targeting Pancreatic Cancer

Apr 15

Candel gets European orphan drug designation for brain, spinal cord tumor treatment

Sep 15

Candel Therapeutics appoints CFO, chief medical officer

Sep 07

Candel Therapeutics: Next-Generation Oncolytic Viral Immunotherapies

Oct 21

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Paul-Peter Tak rispetto agli utili di Candel Therapeutics?
Data	Compenso totale	Stipendio	Guadagni aziendali
Jun 30 2024	n/a	n/a	-US$50m
Mar 31 2024	n/a	n/a	-US$37m
Dec 31 2023	US$1m	US$670k	-US$38m
Sep 30 2023	n/a	n/a	-US$32m
Jun 30 2023	n/a	n/a	-US$32m
Mar 31 2023	n/a	n/a	-US$27m
Dec 31 2022	US$2m	US$670k	-US$19m
Sep 30 2022	n/a	n/a	-US$12m
Jun 30 2022	n/a	n/a	-US$20m
Mar 31 2022	n/a	n/a	-US$33m
Dec 31 2021	US$957k	US$545k	-US$36m
Sep 30 2021	n/a	n/a	-US$48m
Jun 30 2021	n/a	n/a	-US$35m
Mar 31 2021	n/a	n/a	-US$20m
Dec 31 2020	US$3m	US$135k	-US$18m

Compensazione vs Mercato: La retribuzione totale di Paul-Peter ($USD 1.48M ) è circa la media per le aziende di dimensioni simili nel mercato US ($USD 1.54M ).

Compensazione vs guadagni: La retribuzione di Paul-Peter è stata coerente con le performance aziendali dell'ultimo anno.

AMMINISTRATORE DELEGATO

Paul-Peter Tak (63 yo)

4yrs

Mandato

US$1,484,759

Compensazione

Dr. Paul-Peter Tak, M.D. PH.D. FMEDSCI, has been Member of Advisory Board at SecondWave Systems, Inc. from March 2024. He serves as President & Chief Executive Officer at Candel Therapeutics, Inc. since Se...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Paul-Peter Tak	President	4yrs	US$1.48m	0.44% $ 937.7k
Francesca Barone	Chief Scientific Officer	2.6yrs	US$706.88k	0.18% $ 381.9k
Charles Schoch	Interim CFO	1.5yrs	Nessun dato	0.071% $ 150.3k
Seshu Tyagarajan	Chief Technical & Development Officer	2.4yrs	US$916.02k	0.18% $ 374.2k
Ileen Winick	Chief People Officer	no data	Nessun dato	Nessun dato
Susan Stewart	Chief Regulatory Officer	3.9yrs	Nessun dato	Nessun dato
William Nichols	Chief Medical Officer	2yrs	Nessun dato	0.13% $ 268.3k

2.5yrs

Durata media

55.5yo

Età media

Gestione esperta: Il team dirigenziale di CADL è considerato esperto (durata media dell'incarico 2.4 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Paul-Peter Tak	President	4yrs	US$1.48m	0.44% $ 937.7k
Joseph Papa	Independent Director	2.1yrs	US$58.19k	0.12% $ 249.9k
Edward Benz	Member of Research Advisory Board & Director	7yrs	US$56.19k	0% $ 0
Paul Manning	Independent Chairman	5.8yrs	US$83.19k	7.24% $ 15.3m
Scott Eggener	Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato
Adam Kibel	Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato
E. Chiocca	Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato
Christopher Martell	Independent Director	5.8yrs	US$67.19k	2.05% $ 4.3m
Charu Aggarwal	Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato
Steven Albelda	Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato
Mark Bloomston	Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato
Tri Le	Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato

5.8yrs

Durata media

68yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di CADL sono considerati esperti (durata media dell'incarico 5.8 anni).

Candel Therapeutics Gestione

Gestione criteri di controllo 4/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Candel Therapeutics, Inc., Annual General Meeting, Jun 26, 2024

Candel Therapeutics, Inc. Announces Chief Financial Officer Changes

Candel Therapeutics, Inc. Appoints Nicoletta Loggia to the Board of Directors

Candel Therapeutics, Inc., Annual General Meeting, Jun 28, 2023

Independent Director recently bought US$73k worth of stock

Candel Therapeutics Announces Jason A. Amello as Chief Financial Officer, Effective September 21, 2022

Recent updates

Candel Therapeutics: Innovative Cancer Therapies, But Short Cash Runway

Candel Therapeutics, Inc., Annual General Meeting, Jun 26, 2024

Candel Therapeutics Reports Prolonged Overall Survival in Phase 2 Clinical Trial of Can-2409 for Advanced Non-Small Cell Lung Cancer in Patients Non-Responsive to Immune Checkpoint Inhibitor Treatment At 2024 Asco Annual Meeting

Candel Therapeutics: CAN-2409 May Go Beyond Scope Of Targeting Pancreatic Cancer

Candel Therapeutics Presents Preclinical Data At Aacr on Immunotherapy Candidate for Induction of Tertiary Lymphoid Structures in Solid Tumors

Candel Therapeutics, Inc. Announces Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer

New major risk - Share price stability

Candel Therapeutics, Inc Announces Oral Presentation During the 5th Glioblastoma Drug Development Summit with Update on Phase 1b Clinical Trial of CAN-3110 in Recurrent High-Grade Glioma

Candel Therapeutics, Inc. Announces an Upcoming Presentation at the AACR Annual Meeting Unveiling New Cancer Immunotherapy Candidate

Candel Therapeutics, Inc.'s CAN-3110 Receives FDA Fast Track Designation for Treatment of Recurrent High-Grade Glioma

Candel Therapeutics, Inc. Announces Chief Financial Officer Changes

Candel Therapeutics, Inc. Receives FDA Fast Track Designation for CAN-2409 in Pancreatic Cancer

Candel Therapeutics Receives Non-Compliance Notice from Nasdaq

Candel Therapeutics Receives Non-Compliance Notice from Nasdaq

Third quarter 2023 earnings released: US$0.29 loss per share (vs US$0.30 loss in 3Q 2022)

New major risk - Share price stability

Candel Therapeutics, Inc. Announces Initial Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer

Candel Therapeutics, Inc. Announces Nature Publication Showing Extended Survival Associated with Immune Activation in Patients with Recurrent High-Grade Glioma Treated with CAN-3110

Candel Therapeutics, Inc. Announces Nature Publication Showing Extended Survival Associated with Immune Activation in Patients with Recurrent High-Grade Glioma Treated with CAN-3110

Candel Therapeutics, Inc. Reports Encouraging Initial Survival Data from Phase 2 Clinical Trial of CAN-2409 in Non-Small Cell Lung Cancer

Price target increased by 8.6% to US$9.50

First half 2023 earnings released: US$0.64 loss per share (vs US$0.17 loss in 1H 2022)

New major risk - Financial position

New major risk - Share price stability

Candel Therapeutics, Inc. Appoints Nicoletta Loggia to the Board of Directors

Candel Therapeutics, Inc., Annual General Meeting, Jun 28, 2023

Candel Therapeutics Announces New Data from Ongoing Phase 1 Clinical Trial of Can-3110 in Recurrent High-Grade Glioma At the American Society of Gene & Cell Therapy 26Th Annual Meeting

Price target decreased by 17% to US$7.25

First quarter 2023 earnings released: US$0.30 loss per share (vs US$0.03 loss in 1Q 2022)

Full year 2022 earnings released: US$0.65 loss per share (vs US$1.91 loss in FY 2021)

Independent Director recently bought US$73k worth of stock

Consensus forecasts updated

Price target decreased to US$11.60

Candel Therapeutics, Inc. R&D Day Presentations Spotlight Its Advanced Pipeline and Capabilities to Develop Novel Viral Immunotherapies for Patients with Cancer

Candel Therapeutics Announces Oral Presentation of Updated Data from Its Phase 1 Clinical Trial of Can-3110 in 41 Patients with Recurrent High-Grade Glioma At the Society for Neuro-Oncology 27Th Annual Meeting

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Candel Therapeutics Announces Late-Breaking Oral Presentation at SITC Annual Meeting with Data on CAN-2409 in Combination with Nivolumab in a Phase 1 Mechanistic Clinical Trial in Patients with High-Grade Glioma

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Candel gets European orphan drug designation for brain, spinal cord tumor treatment

Candel Therapeutics Announces Jason A. Amello as Chief Financial Officer, Effective September 21, 2022

Candel Therapeutics appoints CFO, chief medical officer

Candel Therapeutics, Inc., Annual General Meeting, Oct 13, 2022

Consensus forecasts updated

Consensus forecasts updated

Less than half of directors are independent

First half 2022 earnings released

Candel Therapeutics, Inc. Announces Executive Changes

Candel Therapeutics, Inc.(NasdaqGM:CADL) dropped from Russell Microcap Value Index

Candel Therapeutics, Inc. Releases Initial Data on CAN-2409 in A Phase 2 Clinical Trial Showing Cytotoxic T Cell Response and Disease Control in Patients with Non-Small Cell Lung Cancer

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Consensus forecasts updated

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Candel Therapeutics, Inc Expects to Present Initial Data from an Ongoing Phase 2 Clinical Trial of CAN-2409

Candel Therapeutics, Inc. Appoints Seshu Tyagarajan as Chief Technical and Development Officer

Candel Therapeutics, Inc. Appoints Seshu Tyagarajan as Chief Technical and Development Officer

Candel Therapeutics, Inc. Appoints Dr. Francesca Barone as Chief Scientific Officer

Candel Therapeutics, Inc. Removes Estuardo Aguilar-Cordova and Laura Aguilar from the Board

Candel Therapeutics, Inc. and Partnership for Accelerating Cancer Therapies to Collaborate on Lung Cancer Trial for CAN-2409

Third quarter 2021 earnings released: US$0.69 loss per share

Candel Therapeutics: Next-Generation Oncolytic Viral Immunotherapies

Chairman recently bought US$411k worth of stock

Analisi delle retribuzioni degli amministratori delegati

AMMINISTRATORE DELEGATO

Mandato

Compensazione

Gruppo dirigente

Durata media

Età media

Membri del Consiglio di amministrazione